Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: The smoothened agonist SAG reduces mitochondrial dysfunction and neurotoxicity of frataxin-deficient astrocytes

Fig. 1

In vitro characterization of FXN silencing in HAs. A–C HAs were transduced with either the LV-scrambled or LV-shRNA37 for the indicated times. A Representative immunoblot and quantification of FXN levels over time after transduction. Equal amounts of protein were immunoblotted and probed with antibodies against FXN and β-actin (as loading control) (n = 5). B Cellular metabolic activity (MTS reduction) in HAs 48, 72 and 96 h post-transduction (n = 7). C Representative immunoblot and quantification of C3 levels over time after transduction. Equal amounts of protein were immunoblotted and probed with antibodies against C3 and β-actin (as loading control) (n = 6). HAs treated for 24 h with IL-1α, TNF-α and C1q were used as a positive control. All values were normalized to the untreated group (data not plotted) of their corresponding time point. Data in all graphs represent mean values ± S.E.M. In A–C data were evaluated by one-way ANOVA followed by Tukey’s post hoc test. In C data from the IL-1α, TNF-α and C1q treated group were compared to the untreated group (data not plotted) using a one-sample t-test

Back to article page